We newly established three HER2-overexpressing gastric cancer cell lines (GLM-1, GLM-2 and GLM-4) from such liver metastasis of Japanese patients (Nakanishi et al, 2005), and demonstrated for the first time that they were highly sensitive to gefitinib rather than trastuzumab. Here, ERBB2 is linked to gastric cancer.